Artelo biosciences receives favorable uk mhra guidance for a phase 1 trial of art12.11, the company's proprietary cbd:tmp cocrystal being developed for the treatment of anxiety and depression

Mhra indicated art12.11 may be a candidate for accelerated development via the innovative licensing and access pathway mhra indicated art12.11 may be a candidate for accelerated development via the innovative licensing and access pathway
ARTL Ratings Summary
ARTL Quant Ranking